Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, non-randomized, single agent, Phase II study of AUY922 in patients
with refractory Gastrointestinal Stromal Tumor (GIST). The primary endpoint of this study is
to determine progression-free survival (PFS) for patients with GIST receiving AUY922
intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle with restaging at 6 and
12 weeks and then every 9 weeks thereafter. Patients may continue treatment until evidence of
disease progression.